(Posted: 07/17/2013) - Costa Rican women who received a vaccine targeting two types of the HPV that cause 70 percent of cervical cancers had the added benefit of protection against oral HPV infection.

(Posted: 07/15/2013) - NCI scientists have developed a comprehensive list of genetic variants for each of the types of cells that comprise what is known as the NCI-60 cell line collection. This new list adds depth to the most frequently studied human tumor cell lines in cancer research, molecular pharmacology, and drug discovery.

(Posted: 07/02/2013) - Scientists report that newly acquired oral HPV infections in healthy men are uncommon and, when present, tend to go away within one year.

(Posted: 06/24/2013) - Investigators in The Cancer Genome Atlas Research Network have uncovered a connection between how tumor cells use energy from metabolic processes and the aggressiveness of the most common form of kidney cancer, clear cell renal cell carcinoma.

(Posted: 06/17/2013) - The process of opening a cancer clinical trial for patient accrual often takes years, and research has shown that trials which are slow to register patients often fail to finish. Following a thorough review, NCI’s Operational Efficiency Working Group produced a series of recommendations that are now being implemented.

(Posted: 06/17/2013) - Researchers have found that antibodies against the human papillomavirus (HPV) may help identify individuals who are at greatly increased risk of HPV-related cancer of the oropharynx, which is a portion of the throat that contains the tonsils.

(Posted: 06/02/2013) - NCI funded a clinical trial that will have an impact on the treatment of late-stage cervical cancer, and also supported a screening trial in India using a network of community outreach workers offering low tech-screening by direct visualization of the cervix coated with dilute acetic acid (vinegar), a process known as VIA. Image depicts cervical cancer microvessel density which increases lethality of the cancer.

(Posted: 06/02/2013) - 3 NCI-funded trials were featured as plenaries at the 2013 ASCO Annual Meeting:
•Visual inspection with acetic acid reduced cervical cancer mortality
•Adding bevacizumab to treatment of recurrent cervical cancer showed survival benefit
•No survival benefit for use of bevacizumab in patients with newly diagnosed glioblastoma

(Posted: 06/02/2013) - Scientists at the National Institutes of Health, and their colleagues, have discovered that a gene called BACH2 may play a central role in the development of diverse allergic and autoimmune diseases, such as multiple sclerosis, asthma, Crohn's disease, celiac disease, and type-1 diabetes.

(Posted: 05/22/2013) - Fungal infections of the skin affect 29 million people in the United States. In the first study of human fungal skin diversity, National Institutes of Health researchers sequenced the DNA of fungi that thrive at different skin sites of healthy adults to define the normal populations across the skin topography and to provide a framework for investigating fungal skin conditions.